Neurizon Therapeutics (ASX:NUZ) appointed Kathryn Williams as chief regulatory officer, Jeffrey Brown as chief scientific adviser, and Chris Freitag as chief medical adviser, according to a Thursday Australian bourse filing.
Williams has 20 years of experience in regulatory affairs, securing fast track and orphan designations with regulatory bodies, the filing said.
Brown also has over 20 years of experience in drug development experience in neurology programs.
Freitag is a medical doctor with nearly 30 years of medical and pharmaceutical experience focusing on oncology and rare diseases.
The company's shares rose 15% in recent Thursday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。